IPP Bureau
AbbVie to acquire Capstan Therapeutics for $2.1 billion
By IPP Bureau - July 01, 2025
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer
By IPP Bureau - July 01, 2025
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Moderna announces promising efficacy results from mRNA flu vaccine trial
By IPP Bureau - July 01, 2025
mRNA-1010 demonstrated superior relative vaccine efficacy
Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery
By IPP Bureau - July 01, 2025
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
PerkinElmer appoints Payal Agrawaal as MD - India & South Asia
By IPP Bureau - July 01, 2025
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Briefs: Lyfius Pharma and Aurobindo Pharma
By IPP Bureau - July 01, 2025
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
Indegene identified as leader in ISG's Provider Lens for life sciences digital services
By IPP Bureau - July 01, 2025
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Biocon Biologics expands insulin access in Malaysia
By IPP Bureau - June 30, 2025
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market
By IPP Bureau - June 30, 2025
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Briefs: Neuland Laboratories and Granules India
By IPP Bureau - June 29, 2025
Granules India receives 1 observation from USFDA for Chantilly facility
Alembic announces USFDA final approval for single-dose vials
By IPP Bureau - June 29, 2025
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France
By IPP Bureau - June 29, 2025
Extended lab space for product development, customer demos, and training
Zambon launches intravenous formulation of Fluimucil
By IPP Bureau - June 29, 2025
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr
By IPP Bureau - June 29, 2025
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Shukra Pharmaceuticals receives LoA from RMSCL
By IPP Bureau - June 28, 2025
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
